Pune, July 22, 2020 (GLOBE NEWSWIRE) -- The global prothrombin complex concentrate (PCC) market size is projected to reach USD 1,604.9 million by 2027, exhibiting a CAGR of 10.6% during the forecast ...

PARAMUS, N.J., July 26, 2023 – Octapharma USA today announced that Balfaxar ® (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octaplex ®) has received U.S. Food and Drug ...

PARAMUS, N.J., April 2, 2025 /PRNewswire/ -- Octapharma USA announced the Journal of the American Medical Association (JAMA) has published results from a Phase III clinical trial, which observed ...

The American Journal of Managed Care® discussed an indirect comparison of andexanet alfa and prothrombin complex concentrate therapy with Alexander T. Cohen, MBBS, MSc, MD, Guy’s and St Thomas’ ...

About The Study: In this unblinded randomized clinical trial, prothrombin complex concentrate had superior hemostatic efficacy and safety advantages to frozen plasma among patients requiring ...

Octapharma USA is offering Balfaxar (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octaplex). The new non-activated four factor prothrombin complex concentrate (4F-PCC) ...

SOUTH SAN FRANCISCO, Calif., July 8, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new in vitro data establishing the relationship between concentrations of the ...

What is Kcentra®/4-factor Prothrombin Complex Concentrate? Kcentra® (4-factor Prothrombin Complex Concentrate), is a blood clotting factor replacement product. It contains clotting factors II, VII, IX ...

Among over 300 patients with the highest trauma level activation, the absolute difference in median total 24-hour blood product consumption between the 4F-PCC and placebo groups was 0.2 U (95% CI ...